Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Orchid Pharma: Cephalosporin drives growth - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Dec 26, 2003

    Orchid Pharma: Cephalosporin drives growth

    Orchid Chemicals & Pharmaceuticals (OCP) is mainly into the manufacture of bulk drugs, formulations and nutraceuticals. The company is the largest manufacturer and exporter of cephalosporin bulk drugs in India and is amongst the top five producers in the world. OCP recently announced its September quarter results. The company has emerged as a preferred choice for Cephalosporin bulk drug, and is reaping the benefits of the same. The company reported a 45% growth in topline and a robust 153% bottomline growth during the quarter.

    Results at a glance ...
    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Net Sales 1,113 1,618 45.4% 2,182 3,348 53.4%
    Other Income 3 1 -48.0% 3 6 109.2%
    Expenditure 891 1,229 37.8% 1,739 2,632 51.3%
    Operating Profit (EBDIT) 222 389 75.5% 442 715 61.7%
    Operating Profit Margin (%) 19.9% 24.1%   20.3% 21.4%  
    Interest 103 166 60.8% 179 277 54.8%
    Depreciation 87 135 55.6% 189 273 44.4%
    Profit before Tax 35 90 159.5% 78 172 121.7%
    Tax 6 17 195.4% 20 23 18.6%
    Profit after Tax/(Loss) 29 73 152.5% 58 149 156.4%
    Net profit margin (%) 2.6% 4.5%   2.7% 4.4%  
    No. of Shares (m) 28 32.4   28 32.4  
    Diluted Earnings per share (Rs)* 3.6 9.0   3.6 9.2  
    P/E Ratio   29.0     28.5  
    (* annualised)            

    During 2QFY04, OCP's bulk drug business (namely cephalosporin) contributed 83% (as against 88% in 2QFY03) to the total gross revenues with the formulations business making up for the rest. Buoyed by introduction of new products and exports, the company's cephalosporin business recorded an impressive 35% growth during 2QFY04 (Rs 1,391 m). Although the formulations business also recorded an impressive 93% growth on the back of strong sales in the Russian and Latin American markets, OCP registered operating losses from this business during the quarter under review.

    Revenue mix by segment
    (Rs m) 2QFY03 2QFY04 % change 1HFY03 1HFY04 % change
    Segment Revenues
    Bulk drugs 1,028 1,391 35.3% 2,000 2,921 46.0%
    Formulations 145 280 93.0% 264 558 111.6%
    Total 1,173 1,671 42.5% 2,264 3,480 53.7%
    Segment Results (Profit before tax and interest)
    Bulk drugs 117 257 119.2% 237 421 77.8%
    Formulations 18 (3) -114.3% 17 21 27.9%
    Total 135 254 88.3% 253 442 74.5%

    On the operations front, OCP registered a 420 basis point improvement in operating profit margins. Although raw material and staff cost as a percentage of net sales increased by 2.2 percentage points and 0.6 percentage points respectively, a sharp drop in other expenditure from 30.2% of net sales in 2QFY03 to 23.2% in 2QFY04 helped the company improve its operating efficiencies. An improvement in operating margins coupled with a less than proportionate rise in interest cost and depreciation provision has helped the company register a sharp 152% growth net profit.

    At Rs 262, OCP is trading at a P/E of 29x annualised 1HFY04 earnings. Given the relatively smaller size and bulk drugs focus on the company, the valuations seem to be stretched. This apart, almost 83% of OCP's September quarter gross revenues were from its cephalosporin bulk drugs business. However, given the company's US-FDA approved plant and joint venture in China, OCP is well placed to capitalize on the contract manufacturing opportunities that may come its way.



    Equitymaster requests your view! Post a comment on "Orchid Pharma: Cephalosporin drives growth". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Compare Company With Charts